The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy ...

China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...

Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% of ...

Vor Bio to wind down, halting cell therapy trials and shedding most staff Focusing on NGM120 means setting aside aldafermin, an engineered FGF19 hormone with a troubled history. The asset had ...

Abbisko Cayman Limited ( ($HK:2256) ) has provided an announcement. Abbisko Therapeutics has announced that its small molecule FGFR4 inhibitor, ...

The designation is expected to accelerate the regulatory process for the therapy, offering hope to those with hepatocellular carcinoma. Credit: SewCreamStudio ...

Research shows how hormone can reverse fatty liver disease in mice Like GLP-1, hormone works by signaling the brain Date: May 14, 2025 Source: University of Oklahoma Summary: A pioneering research ...

A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set—T790M negative (n = 62) and T790M positive (n = 2). The median OS in the ...

Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer FGFR2b protein ...

Over the past decade, intensive studies have shown that the brain's meningeal lymphatic system acts as the brain's "waste disposal network," maintaining homeostasis by clearing metabolic waste and ...